![Tomas Jan Heyman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tomas Jan Heyman
Fortuna: 2 M $ al 31/12/2025
Perfil
Tomas Jan Heyman is Chief Executive Officer at Interlaken Therapeutics, Inc. He is an Independent Director at Exelixis, Inc. since 2023.
He serves as Director at Interuniversitair Micro-Electronica Centrum VZW since 2012.
He is Director at Primmune Therapeutics, Inc. He is an Independent Director at Legend Biotech Corp.
since 2022.
Former roles include Chairman & Chief Executive Officer at Janssen Pharmaceutica NV from 2008 to 2016.
Non-Executive Chairman at Venatorx Pharmaceuticals, Inc. from 2023 to 2024.
Independent Director at Invivyd, Inc. from 2021 to 2024.
Independent Director at OptiNose, Inc. from 2020 to 2025.
Director at CVRx, Inc. Former Director at International Biomedical Research Alliance.
Independent Director at Xilio Therapeutics, Inc. from 2022 to 2024.
Independent Director at Akero Therapeutics, Inc. from 2020 to 2025.
Member-Supervisory Board at Crucell NV.
President at Johnson & Johnson Innovation - JJDC, Inc. Vice President-Licensing at Ortho Pharmaceutical Corp.
Global Head-Business Development at Janssen Global Services LLC from 1992 to 2015.
Global Head-Business Development at Johnson & Johnson from 2015 to 2019.
Education includes graduate degrees from Katholieke Universiteit Leuven and the University of Antwerp.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
EXELIXIS, INC. 0,02 % | 29/05/2025 | 42.282 ( 0,02 % ) | 2 M $ | 31/12/2025 |
LEGEND BIOTECH CORP. 0,01 % | 11/03/2025 | 15.652 ( 0,01 % ) | 170 137 $ | 31/12/2025 |
Cargos activos de Tomas Jan Heyman
| Empresas | Cargo | Inicio |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Director/Miembro de la Junta | 02/08/2022 |
| EXELIXIS, INC. | Director/Miembro de la Junta | 31/05/2023 |
Interuniversitair Micro-Electronica Centrum VZW
 Interuniversitair Micro-Electronica Centrum VZW Engages in research and development of nano electronics and digital technology products | Director/Miembro de la Junta | 27/04/2012 |
Interlaken Therapeutics, Inc. | Director Ejecutivo | - |
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Develops orally administered toll-like receptor for cancer immunotherapy | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Tomas Jan Heyman.
| Empresas | Cargo | Fin |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Director/Miembro de la Junta | 09/12/2025 |
| OPTINOSE, INC. | Director/Miembro de la Junta | 21/05/2025 |
| XILIO THERAPEUTICS, INC. | Director/Miembro de la Junta | 13/06/2024 |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | Presidente | 16/05/2024 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | ░░░░░░░░░░ |
Formación de Tomas Jan Heyman.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 20 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Operates as an investment holding company with interests in health care products | |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Develops, produces and markets vaccines, proteins and antibodies | Health Technology |
OptiNose, Inc.
 OptiNose, Inc. Operates as a pharmaceutical company that develops and commercializes products for patients treated by ear, nose, throat and allergy diseases | |
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Develops novel anti-infectives to treat multi-drug-resistant bacterial and viral infections | |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
CVRx, Inc.
 CVRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes neuromodulation device & implantable technology to treat hypertension and heart failure | Health Technology |
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Biomedical Research Alliance
 International Biomedical Research Alliance Miscellaneous Commercial ServicesCommercial Services Provides doctoral training program for science students committed to biomedical research careers | Commercial Services |
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Engages in research, development and production of drugs | Health Technology |
Ortho Pharmaceutical Corp. | |
Interuniversitair Micro-Electronica Centrum VZW
Interuniversitair Micro-Electronica Centrum VZW Engages in research and development of nano electronics and digital technology products | |
University of Antwerp
 University of Antwerp Functions as a College/University | |
Janssen Global Services LLC
 Janssen Global Services LLC Develops treatments for patients in therapeutic areas of healthcare | |
Legend Biotech Corp.
 Legend Biotech Corp. Operates as clinical-stage biopharmaceutical company which engages in the discovery and development of novel cell therapies for oncology | |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Develops orally administered toll-like receptor for cancer immunotherapy | |
Akero Therapeutics, Inc.
 Akero Therapeutics, Inc. Develops therapies for patients with metabolic diseases | |
Invivyd, Inc.
 Invivyd, Inc. Develops antibody-based solutions for infectious diseases | |
Interlaken Therapeutics, Inc. |
- Bolsa de valores
- Insiders
- Tomas Jan Heyman
